Abstract
Objective
To discuss the expected future development and implications of the US biotechnologic pharmaceutical industry. Foreign competition and internal forces that might impede the industry are also discussed.
Data Sources
Searches were conducted in the Business Periodicals Index and the International Pharmaceutical Abstracts databases.
Study Selection
All studies pertaining to the business of biotechnology were reviewed.
Conclusions
Biotechnologically produced agents will require a shorter period of development and a less costly production process, and will be generally safer than conventional drugs. Furthermore, these agents will afford superior pharmacotherapy to that of conventional drugs, enhancing the diagnosis and treatment of diseases as harrowing as AIDS and neoplastic disorders.
Get full access to this article
View all access options for this article.